Trial · NCT05087706
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
NCT05087706, Unknown, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）. Trials, record NCT05087706. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05087706
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
- NCT number
- NCT05087706
- Status
- Unknown
- Enrollment
- 182 participants, estimated
- Lead sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Conditions
- Salivary Gland Neoplasms
- Interventions
- Pyrotinib, Bicalutamide, Leuprorelin
- First posted
- 2021-10-21
- Last updated
- 2021-10-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Molecular mutation profile of patients with salivary gland cancer | 18 months | To explore the complete picture of molecular mutations in locally advanced and advanced salivary gland tumors in China |
| Primary | Proportion of patients who receive molecular guided therapy | 18 months | Proportion of patients who have actionable genomic alterations and receive matched therapy based on genomic profile(s) |
| Secondary | Progression-free survival (PFS) in patients | 2 years | PFS of patients with locally advanced and advanced salivary gland cancer |
| Secondary | Objective Response Rate (ORR) | 2 years | ORR in patients with advanced salivary gland cancer |
| Secondary | Overall Survival (OS) | 2 years | OS of patients with locally advanced and advanced salivary gland cancer |
| Secondary | Proportion of patients with actionable genomic alteration | 2 years | To calculate the proportion of patients with actionable genomic alteration(s) |
| Secondary | Treatment-related adverse events (AEs) | 2 years | The grade of AEs and the number of patients with AEs are assessed by the investigator based on CTCAE v5.0 from the date of enrollment to 90 days after last dose of study treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05087706
GET https://conductscience.org/api/trials/v1/NCT05087706/registered